Phase I evaluation of vascular disrupting agent OXi4503

被引：0
|
作者：
Patterson, D. M.
Charnley, N.
Saleem, A.
Stratford, M.
Dickinson, C.
Asselin, M.
Ross, P.
Walicke, P.
Price, P.
Rustin, G. J.
机构：
[1] Mt Vernon Hosp, Northwood HA6 2RN, Middx, England
[2] Christie Hopsital, Manchester, Lancs, England
[3] Gray Canc Inst, Northwood, Middx, England
[4] Canc Res UK, London, England
[5] Oxigene, Waltham, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3551
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Evaluations of vascular disrupting agents CA4P and OXi4503 in renal cell carcinoma (Caki-1) using a silicon based microvascular casting technique
    Salmon, Howard W.
    Mladinich, Christopher
    Siemann, Dietmar W.
    [J]. EUROPEAN JOURNAL OF CANCER, 2006, 42 (17) : 3073 - 3078
  • [32] Using proton radiation or OXi4503 to convert non-immunogenic tumours into immune responders
    Horsman, M.
    Nygaard, S.
    Nielsen, S.
    Sitarz, M.
    Poulsen, P.
    Hoyer, M.
    Sorensen, B.
    Elming, P.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2022, 170 : S222 - S222
  • [33] Support of a free radical mechanism for enhanced antitumor efficacy of the microtubule disruptor OXi4503
    Rice, Lori
    Pampo, Christine
    Lepler, Sharon
    Rojiani, Amyn M.
    Siemann, Dietmar W.
    [J]. MICROVASCULAR RESEARCH, 2011, 81 (01) : 44 - 51
  • [34] Investigating tumor vasculature development and the effects of OXi4503 by non-invasive photoacoustic imaging
    Johnson, Sean Peter
    Ogunlade, Ollie
    Zhang, Edward
    Lythgoe, Mark
    Beard, Paul
    Pedley, Rosamund Barbara
    [J]. CANCER RESEARCH, 2015, 75 (01)
  • [35] Combing hyperthermia and/or OXi4503 with low LET radiation is equivalent to high LET radiation alone
    Elming, P. B.
    Sorensen, B. S.
    Spejlborg, H.
    Overgaard, J.
    Horsman, M. R.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2019, 133 : S308 - S308
  • [36] Use of whole genome expression analysis of pancreatic adenocarcinoma to predict prognosis after OXi4503 surgery
    Collisson, E. A.
    Das, D.
    Mori, R.
    Hoffmann, A. C.
    Kim, G. E.
    Hajnal, R.
    Danenberg, P. V.
    Cooc, J.
    Danenberg, K. D.
    Tempero, M. A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [37] Evaluating the Potential of OXi4503 to Enhance Tumour Response to Radiation Administered in Clinically Relevant Conventional or Stereotactic Schedules
    Horsman, M. R.
    [J]. EUROPEAN JOURNAL OF CANCER, 2012, 48 : 192 - 192
  • [38] Mechanism of action of the vascular disrupting agent OXi8006 on activated endothelial cell signaling
    Taylor, Emily A.
    Odutola, Sam O.
    Strecker, Tracy E.
    Hayashi, Merrick M.
    MacDonough, Matthew T.
    Pinney, Kevin G.
    Trawick, Mary Lynn
    [J]. FASEB JOURNAL, 2018, 32 (01):
  • [39] OXI 4503 a novel vascular targeting agent: Effects on bloodflow and antitumor activity in comparison to Combretastatin A-4 phosphate
    Edvardsen, K
    Hua, J
    Sheng, Y
    Pinney, K
    Kane, R
    Prezioso, J
    Chaplin, D
    [J]. EUROPEAN JOURNAL OF CANCER, 2002, 38 : S43 - S43
  • [40] Safety, feasibility and preliminary efficacy of single agent combretastatin A1 diphosphate (OXi4503) in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndromes
    Cogle, Christopher R.
    Collins, Bradley
    Turner, Daniel
    Pettiford, Leslie C.
    Bosse, Raphael
    Hawkins, Kimberly E.
    Beachamp, Zackary
    Wise, Elizabeth
    Cline, Christina
    May, William S.
    Moreb, Jan S.
    Hsu, Jack
    Hiemenz, John
    Brown, Randall
    Norkin, Maxim
    Wingard, John R.
    Uckun, Fatih
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 (05) : E211 - E213
12345